Vamotinib

DB15396InvestigationalSmall molecule

Vamotinib (PF-114) is under investigation in clinical trial NCT02885766 (Study to Evaluate Tolerability, Safety, Pharmacokinetics and Preliminary Efficacy of PF-114 for Oral Administration in Adults With Ph+ Chronic Myeloid Leukemia,...

Mechanism: Pharmacologically active on Tyrosine-protein kinase ABL1 and Breakpoint cluster region protein
Curator reviewed
Formula / weight: C₂₉H₂₇F₃N₆O · 532.571 g/mol (avg)
Code names: PF-114

Resolves to

Compound

UNIII8C3R768IZCAS1416241-23-0ChEMBLCHEMBL4297478

Structure

InChIKeySLIVDYMORZGPLW-UHFFFAOYSA-NSMILESCN1CCN(CC2=C(C=C(NC(=O)C3=CC=C(C)C(=C3)C#CC3=NN=C4C=CC=CN34)C=C2)C(F)(F)F)CC1

Targets

P00519ABL1P11274BCR

What you can answer from here — as of July 08, 2026

2Protein targetsEach mapped to UniProt, with action and pharmacological action

Listed above

1Clinical trialPhase, status and sponsor resolved per trial

4+ReferencesStructured and connected to the statements they support

Which drugs share a target with Vamotinib, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account